Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 647 | 16.73 |
09:38 ET | 200 | 16.7397 |
09:39 ET | 200 | 16.55 |
09:41 ET | 764 | 16.52 |
09:50 ET | 8440 | 16.63 |
09:52 ET | 9050 | 16.675 |
09:54 ET | 900 | 16.67 |
10:06 ET | 200 | 16.5 |
10:08 ET | 300 | 16.4 |
10:12 ET | 200 | 16.4699 |
10:15 ET | 1300 | 16.32 |
10:19 ET | 100 | 16.31 |
10:21 ET | 1097 | 16.3 |
10:26 ET | 100 | 16.24 |
10:32 ET | 228 | 16.236 |
10:35 ET | 510 | 16.16 |
10:42 ET | 200 | 16.1 |
10:48 ET | 2200 | 16.05 |
10:53 ET | 200 | 16.1 |
10:55 ET | 200 | 16.04 |
10:57 ET | 216 | 16.05 |
11:02 ET | 6922 | 16.13 |
11:06 ET | 600 | 16.185 |
11:08 ET | 1600 | 16.17 |
11:09 ET | 2500 | 16.17 |
11:11 ET | 200 | 16.17 |
11:13 ET | 100 | 16.16 |
11:18 ET | 126 | 16.1 |
11:20 ET | 695 | 16.03 |
11:31 ET | 3758 | 16.04 |
11:33 ET | 2194 | 16.0654 |
11:36 ET | 600 | 16.09 |
11:38 ET | 200 | 16.12 |
11:56 ET | 500 | 16.12 |
12:03 ET | 507 | 16.13 |
12:18 ET | 100 | 16.205 |
12:27 ET | 1550 | 16.07 |
12:30 ET | 456 | 16.115 |
12:45 ET | 200 | 16.17 |
12:52 ET | 1380 | 16.13 |
12:54 ET | 584 | 16.16 |
12:59 ET | 400 | 16.13 |
01:03 ET | 1351 | 16.12 |
01:08 ET | 528 | 16.17 |
01:14 ET | 200 | 16.16 |
01:17 ET | 400 | 16.12 |
01:21 ET | 500 | 16.07 |
01:24 ET | 600 | 16.05 |
01:26 ET | 1600 | 16.04 |
01:37 ET | 100 | 16.12 |
01:39 ET | 3700 | 16.175 |
01:42 ET | 300 | 16.15 |
01:44 ET | 400 | 16.18 |
01:46 ET | 9057 | 16.1206 |
01:48 ET | 100 | 16.185 |
01:53 ET | 100 | 16.13 |
01:55 ET | 100 | 16.185 |
01:57 ET | 1075 | 16.13 |
02:00 ET | 1292 | 16.15 |
02:04 ET | 100 | 16.1 |
02:06 ET | 300 | 16.1 |
02:11 ET | 11600 | 16.21 |
02:13 ET | 499 | 16.2065 |
02:24 ET | 923 | 16.2 |
02:29 ET | 300 | 16.2 |
02:31 ET | 1523 | 16.2 |
02:33 ET | 100 | 16.2 |
02:38 ET | 200 | 16.21 |
02:40 ET | 100 | 16.21 |
02:42 ET | 300 | 16.21 |
02:45 ET | 200 | 16.21 |
02:47 ET | 3983 | 16.11 |
02:49 ET | 5447 | 16.15 |
02:54 ET | 100 | 16.185 |
02:58 ET | 616 | 16.16 |
03:00 ET | 100 | 16.16 |
03:02 ET | 200 | 16.195 |
03:03 ET | 300 | 16.2 |
03:07 ET | 1005 | 16.17 |
03:09 ET | 1528 | 16.15 |
03:12 ET | 400 | 16.13 |
03:14 ET | 1658 | 16.115 |
03:20 ET | 950 | 16.15 |
03:21 ET | 1135 | 16.19 |
03:23 ET | 100 | 16.19 |
03:25 ET | 400 | 16.2 |
03:27 ET | 900 | 16.25 |
03:30 ET | 600 | 16.24 |
03:32 ET | 450 | 16.24 |
03:34 ET | 1388 | 16.19 |
03:36 ET | 565 | 16.18 |
03:38 ET | 1712 | 16.18 |
03:39 ET | 2503 | 16.15 |
03:41 ET | 300 | 16.13 |
03:43 ET | 209 | 16.09 |
03:45 ET | 1915 | 16 |
03:48 ET | 1747 | 15.96 |
03:50 ET | 3308 | 15.92 |
03:52 ET | 925 | 15.88 |
03:54 ET | 3646 | 15.83 |
03:56 ET | 7691 | 15.83 |
03:57 ET | 4727 | 15.76 |
03:59 ET | 4145 | 15.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 515.9M | -5.8x | --- |
Arrivent Biopharma Inc | 512.5M | -7.2x | --- |
Allogene Therapeutics Inc | 519.0M | -1.4x | --- |
Nkarta Inc | 503.3M | -2.8x | --- |
Adlai Nortye Ltd | 500.0M | -8.0x | --- |
Altimmune Inc | 501.9M | -4.4x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $515.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-2.70 |
Book Value | $5.48 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.